CGTX's Business Model
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.cogrx.com |
| CEO (Chief Executive Officer) | Lisa Ricciardi |
| Number of Employees | |
| IPO date | October 8, 2021 |
CGTX Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 2500 Westchester Avenue |
| City | Purchase |
| State | NY |
| Phone | 412 481 2210 |
| Zip Code | 10577 |
| Other Identifiers | |
| CIK | 0001455365 |
| ISIN | US19243B1026 |
| CUSIP | 19243B102 |
| Open | 1.1 |
| Previous Close | 1.08 |
| Volume | 402.8 Thou. |
| Average Volume | 853.5 Thou. |
| Day’s Range | 1.045 – 1.11 |
| 52 Week Range | 0.222-3.83 |
| MA (50) | 1.2074 |
| MA (200) | 1.28448 |
| Market Cap | 77.26 Mil. |
| Shares Out. | 73.58 Mil. |
| Earnings Date | Apr 01, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
